

Ana Rovira

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7803837/publications.pdf>

Version: 2024-02-01

94
papers

4,732
citations

100601

38
h-index

120465

65
g-index

99
all docs

99
docs citations

99
times ranked

10386
citing authors

#	ARTICLE	IF	CITATIONS
1	mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer. <i>Molecular Cancer Research</i> , 2022, 20, 1108-1121.	1.5	5
2	CIP2A as a Key Regulator for AKT Phosphorylation Has Partial Impact Determining Clinical Outcome in Breast Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 1610.	1.0	1
3	Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer. <i>Science Advances</i> , 2022, 8, .	4.7	21
4	Targeted metabolomics in formalin-fixed paraffin-embedded tissue specimens: Liquid chromatography-tandem mass spectrometry determination of acidic metabolites in cancer research. <i>Talanta</i> , 2021, 223, 121740.	2.9	7
5	Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5096-5108.	3.2	12
6	CD137 Costimulation Counteracts TGF β 2 Inhibition of NK-cell Antitumor Function. <i>Cancer Immunology Research</i> , 2021, 9, 1476-1490.	1.6	15
7	Targeted Therapy Modulates the Secretome of Cancer-Associated Fibroblasts to Induce Resistance in HER2-Positive Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13297.	1.8	8
8	Facing privacy in neuroimaging: removing facial features degrades performance of image analysis methods. <i>European Radiology</i> , 2020, 30, 1062-1074.	2.3	30
9	Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation. <i>Clinical Cancer Research</i> , 2020, 26, 1432-1448.	3.2	54
10	Autocrine CCL5 Effect Mediates Trastuzumab Resistance by ERK Pathway Activation in HER2-Positive Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1696-1707.	1.9	24
11	HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 2135-2145.	1.9	30
12	Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3K β Inhibitor TAK-117 in Preclinical Bladder Cancer Models. <i>Molecular Cancer Research</i> , 2019, 17, 1931-1944.	1.5	23
13	High Numbers of Circulating CD57+ NK Cells Associate with Resistance to HER2-Specific Therapeutic Antibodies in HER2+ Primary Breast Cancer. <i>Cancer Immunology Research</i> , 2019, 7, 1280-1292.	1.6	25
14	Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer. <i>Oncolmmunology</i> , 2019, 8, e1593810.	2.1	44
15	The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors. <i>Scientific Reports</i> , 2019, 9, 5316.	1.6	62
16	NK Cell Infiltrates and HLA Class I Expression in Primary HER2+ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival. <i>Clinical Cancer Research</i> , 2019, 25, 1535-1545.	3.2	86
17	Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses. <i>JAMA Oncology</i> , 2018, 4, e175245.	3.4	98
18	MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer. <i>Nature Cell Biology</i> , 2018, 20, 211-221.	4.6	98

#	ARTICLE	IF	CITATIONS
19	Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab. <i>Oncolmunology</i> , 2018, 7, e1395125.	2.1	26
20	Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations. <i>Genome Medicine</i> , 2018, 10, 25.	3.6	366
21	Recent Insights into the Development of Preclinical Trastuzumab- Resistant HER2+ Breast Cancer Models. <i>Current Medicinal Chemistry</i> , 2018, 25, 1976-1998.	1.2	3
22	CIP2A confirms its prognostic value in triple-negative breast cancer. <i>Oncogene</i> , 2017, 36, 3357-3358.	2.6	9
23	The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene. <i>Scientific Reports</i> , 2017, 7, 41309.	1.6	62
24	Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 7006-7019.	3.2	61
25	Comparison between gadolinium-enhanced 2D T1-weighted gradient-echo and spin-echo sequences in the detection of active multiple sclerosis lesions on 3.0T MRI. <i>European Radiology</i> , 2017, 27, 1361-1368.	2.3	5
26	Measurement of Cortical Thickness and Volume of Subcortical Structures in Multiple Sclerosis: Agreement between 2D Spin-Echo and 3D MPRAGE T1-Weighted Images. <i>American Journal of Neuroradiology</i> , 2017, 38, 250-256.	1.2	9
27	Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2017, 8, 1544.	2.2	71
28	c-Jun N-Terminal Kinase Inactivation by Mitogen-Activated Protein Kinase Phosphatase 1 Determines Resistance to Taxanes and Anthracyclines in Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2780-2790.	1.9	13
29	Non-canonical NF- κ B pathway activation predicts outcome in borderline oestrogen receptor positive breast carcinoma. <i>British Journal of Cancer</i> , 2016, 115, 322-331.	2.9	21
30	FoxA and LIPG endothelial lipase control the uptake of extracellular lipids for breast cancer growth. <i>Nature Communications</i> , 2016, 7, 11199.	5.8	50
31	The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 3260-3267.	3.2	62
32	Lesion filling effect in regional brain volume estimations: a study in multiple sclerosis patients with low lesion load. <i>Neuroradiology</i> , 2016, 58, 467-474.	1.1	23
33	Enhancing tumor-targeting monoclonal antibodies therapy by PARP inhibitors. <i>Oncolmunology</i> , 2016, 5, e1065370.	2.1	6
34	Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines. <i>American Journal of Cancer Research</i> , 2016, 6, 2661-2678.	1.4	13
35	Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2157-2166.	3.2	227
36	Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv256.	3.0	90

#	ARTICLE	IF	CITATIONS
37	Angiotensin-2 is a negative prognostic marker in small cell lung cancer. <i>Lung Cancer</i> , 2015, 90, 302-306.	0.9	18
38	Snail1-Expressing Fibroblasts in the Tumor Microenvironment Display Mechanical Properties That Support Metastasis. <i>Cancer Research</i> , 2015, 75, 284-295.	0.4	92
39	Significant clinical worsening after natalizumab withdrawal: Predictive factors. <i>Multiple Sclerosis Journal</i> , 2015, 21, 780-785.	1.4	43
40	Brain atrophy in natalizumab-treated patients: A 3-year follow-up. <i>Multiple Sclerosis Journal</i> , 2015, 21, 749-756.	1.4	51
41	PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects. <i>Oncotarget</i> , 2015, 6, 4299-4314.	0.8	87
42	Increased myo-inositol in parietal white and gray matter as a biomarker of poor prognosis in neuropsychiatric lupus: a case report. <i>Lupus</i> , 2014, 23, 1073-1078.	0.8	12
43	Methylation status of <i>IGFBP-3</i> as a useful clinical tool for deciding on a concomitant radiotherapy. <i>Epigenetics</i> , 2014, 9, 1446-1453.	1.3	13
44	Gene Expression Profiling in True Interval Breast Cancer Reveals Overactivation of the mTOR Signaling Pathway. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 288-299.	1.1	10
45	Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer. <i>European Journal of Cancer</i> , 2014, 50, 2725-2734.	1.3	25
46	Targeting Epithelial-to-Mesenchymal Transition with Met Inhibitors Reverts Chemoresistance in Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 938-950.	3.2	110
47	Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF- κ B target genes in human breast cancer. <i>Oncotarget</i> , 2014, 5, 196-210.	0.8	36
48	High circulating hepatocyte growth factor levels associate with epithelial to mesenchymal transition and poor outcome in small cell lung cancer patients. <i>Oncotarget</i> , 2014, 5, 5246-5256.	0.8	33
49	Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. <i>Nature Medicine</i> , 2012, 18, 221-223.	15.2	434
50	Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer. <i>Annals of Oncology</i> , 2012, 23, 1156-1164.	0.6	144
51	Inhibition of Specific NF- κ B Activity Contributes to the Tumor Suppressor Function of 14-3-3 β in Breast Cancer. <i>PLoS ONE</i> , 2012, 7, e38347.	1.1	25
52	El complex <i>Euphorbia esula-E. virgata</i> (Euphorbiaceae) al nord-est de la península Ibèrica: precisions corolàgiques, ecològiques i taxonòmiques. <i>Collectanea Botanica</i> , 2012, 31, 37-49.	0.2	2
53	Increased ALK Gene Copy Number and Amplification are Frequent in Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 21-27.	0.5	144
54	DUSP1/MKP1 promotes angiogenesis, invasion and metastasis in non-small-cell lung cancer. <i>Oncogene</i> , 2011, 30, 668-678.	2.6	77

#	ARTICLE	IF	CITATIONS
55	Shift towards autogamy in the extremely narrow endemic <i>Aquilegia paui</i> and comparison with its widespread close relative <i>A. vulgaris</i> (Ranunculaceae). <i>Plant Systematics and Evolution</i> , 2011, 295, 73-82.	0.3	4
56	Nuclear NF- κ B/p65 expression and response to neoadjuvant chemotherapy in breast cancer. <i>Journal of Clinical Pathology</i> , 2011, 64, 130-135.	1.0	25
57	MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines. <i>British Journal of Cancer</i> , 2011, 105, 814-823.	2.9	48
58	C-MET as a new therapeutic target for the development of novel anticancer drugs. <i>Clinical and Translational Oncology</i> , 2010, 12, 253-260.	1.2	47
59	Nocturnal pollination of the endemic <i>Silene sennenii</i> (Caryophyllaceae): an endangered mutualism?. <i>Plant Ecology</i> , 2010, 211, 203-218.	0.7	21
60	Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients. <i>British Journal of Cancer</i> , 2010, 102, 1137-1144.	2.9	24
61	Pharmacodynamic Trial of Nimotuzumab in Unresectable Squamous Cell Carcinoma of the Head and Neck: A SENDO Foundation Study. <i>Clinical Cancer Research</i> , 2010, 16, 2474-2482.	3.2	54
62	Mitogen-Activated Protein Kinase Phosphatase-1 in Human Breast Cancer Independently Predicts Prognosis and Is Repressed by Doxorubicin. <i>Clinical Cancer Research</i> , 2009, 15, 3530-3539.	3.2	52
63	Cytogenetic characterization of NCI-H69 and NCI-H69AR small cell lung cancer cell lines by spectral karyotyping. <i>Cancer Genetics and Cytogenetics</i> , 2009, 191, 97-101.	1.0	7
64	MKP1 repression is required for the chemosensitizing effects of NF- κ B and PI3K inhibitors to cisplatin in non-small cell lung cancer. <i>Cancer Letters</i> , 2009, 286, 206-216.	3.2	22
65	FISH and immunohistochemical status of the hepatocyte growth factor receptor (c-Met) in 184 invasive breast tumors. <i>Breast Cancer Research</i> , 2009, 11, 402.	2.2	22
66	Genetic changes in small cell lung carcinoma. <i>Clinical and Translational Oncology</i> , 2008, 10, 189-197.	1.2	32
67	Targeted therapies in breast cancer. <i>Seminars in Diagnostic Pathology</i> , 2008, 25, 245-261.	1.0	39
68	Inhibition of the Canonical IKK/NF- κ B Pathway Sensitizes Human Cancer Cells to Doxorubicin. <i>Cell Cycle</i> , 2007, 6, 2284-2292.	1.3	66
69	mTOR signaling in human cancer. <i>Clinical and Translational Oncology</i> , 2007, 9, 484-493.	1.2	54
70	The proteasome: a novel target for anticancer therapy. <i>Clinical and Translational Oncology</i> , 2006, 8, 313-317.	1.2	65
71	Activation of nuclear factor- κ B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients. <i>Endocrine-Related Cancer</i> , 2006, 13, 607-616.	1.6	86
72	Interleukin 6, a Nuclear Factor- κ B Target, Predicts Resistance to Docetaxel in Hormone-Independent Prostate Cancer and Nuclear Factor- κ B Inhibition by PS-1145 Enhances Docetaxel Antitumor Activity. <i>Clinical Cancer Research</i> , 2006, 12, 5578-5586.	3.2	147

#	ARTICLE	IF	CITATIONS
73	Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 665-675.	1.9	98
74	Pharmacological inhibition and silencing of classical IKK-NF- κ B pathway by siRNA sensitizes cancer cells to doxorubicin. <i>Journal of Clinical Oncology</i> , 2006, 24, 2059-2059.	0.8	25
75	Activation of nuclear factor- κ B in human prostate carcinogenesis and association to biochemical relapse. <i>British Journal of Cancer</i> , 2005, 93, 1285-1294.	2.9	109
76	A Carboxypeptidase Inhibitor from the Tick <i>Rhipicephalus bursa</i> . <i>Journal of Biological Chemistry</i> , 2005, 280, 3441-3448.	1.6	70
77	Preclinical and clinical development of the proteasome inhibitor bortezomib in cancer treatment. <i>Drugs of Today</i> , 2005, 41, 299.	2.4	21
78	Water-soluble platinum(II) complexes of diamine chelating ligands bearing amino-acid type substituents: the effect of the linked amino acid and the diamine chelate ring size on antitumor activity, and interactions with 5'-GMP and DNA. <i>Journal of Inorganic Biochemistry</i> , 2004, 98, 1933-1946.	1.5	39
79	Secondary Binding Site of the Potato Carboxypeptidase Inhibitor. Contribution to Its Structure, Folding, and Biological Properties. <i>Biochemistry</i> , 2004, 43, 7973-7982.	1.2	18
80	Platinum complexes of diaminocarboxylic acids and their ethyl ester derivatives: the effect of the chelate ring size on antitumor activity and interactions with GMP and DNA. <i>Journal of Inorganic Biochemistry</i> , 2003, 96, 493-502.	1.5	45
81	Mechanism of Action of Anti-Her2 Monoclonal Antibodies: Scientific Update on Trastuzumab and 2c4. <i>Advances in Experimental Medicine and Biology</i> , 2003, 532, 253-268.	0.8	173
82	Frequency of Missense Mutations in the Coding Region of a Eukaryotic Gene Transferred by Retroviral Vectors. <i>Journal of Virology</i> , 2002, 76, 1991-1994.	1.5	5
83	Karyological evolution and molecular phylogeny in Macaronesian dendroid spurges (<i>Euphorbia</i>) Tj ETQq1 1 0.784314 rgBT /Overlock 10 0.3 42		
84	Glucose 6-phosphate dehydrogenase expression is less prone to variegation when driven by its own promoter. <i>Gene</i> , 2001, 267, 221-231.	1.0	7
85	Stable in vivo expression of glucose-6-phosphate dehydrogenase (G6PD) and rescue of G6PD deficiency in stem cells by gene transfer. <i>Blood</i> , 2000, 96, 4111-4117.	0.6	25
86	Stable in vivo expression of glucose-6-phosphate dehydrogenase (G6PD) and rescue of G6PD deficiency in stem cells by gene transfer. <i>Blood</i> , 2000, 96, 4111-4117.	0.6	1
87	Stable in vivo expression of glucose-6-phosphate dehydrogenase (G6PD) and rescue of G6PD deficiency in stem cells by gene transfer. <i>Blood</i> , 2000, 96, 4111-7.	0.6	7
88	Two new mutations of the glucose-6-phosphate dehydrogenase (G6PD) gene associated with haemolytic anaemia: clinical, biochemical and molecular relationships. <i>British Journal of Haematology</i> , 1997, 98, 578-582.	1.2	14
89	Congenital 6-phosphogluconate dehydrogenase (6PGD) deficiency associated with chronic hemolytic anemia in a Spanish family. , 1996, 53, 221-227.		12
90	Independent origin of single and double mutations in the human glucose 6-phosphate dehydrogenase gene. , 1996, 8, 311-318.		18

#	ARTICLE	IF	CITATIONS
91	Molecular genetics of glucose-6-phosphate dehydrogenase (G6PD) deficiency in Spain: identification of two new point mutations in the G6PD gene. <i>British Journal of Haematology</i> , 1995, 91, 66-71.	1.2	25
92	P53 Tumor suppressor gene in chronic myelogenous leukemia: A sequential study. <i>Annals of Hematology</i> , 1995, 70, 129-133.	0.8	13
93	The glucose-6-phosphate dehydrogenase (G6PD) deficient variant G6PD union (454 Argâ†’Cys) has a worldwide distribution possibly due to recurrent mutation. <i>Human Molecular Genetics</i> , 1994, 3, 833-835.	1.4	17
94	Study of Titanium Metal Matrix Composites Reinforced by Boron Carbides and Amorphous Boron Particles Produced via Direct Hot Pressing. <i>Key Engineering Materials</i> , 0, 704, 85-93.	0.4	4